Limited Offer
Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 37-5 - September 15, 2023
- Editors: Bradley A. Mcgregor, Toni K. Choueiri
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 3 8 9 9 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 3 9 0 0 - 3
In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote-
Contains 18 relevant, practice-oriented topics including the role of surgery in metastatic renal cell cancer; emerging biomarkers in metastatic renal cell cancer; choosing the right treatment for renal cell cancer of variant histology; novel targets in the treatment of renal cell cancer; and more.
-
Provides in-depth clinical reviews on renal cell cancer, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
- Kidney cancer
- von Hippel-Lindau disease
- von Hippel-Lindau and sporadic clear cell renal cell carcinoma
- Cooperating mutations
- The von Hippel-Lindau tumor suppressor protein
- The hypoxia-inducible factor transcription factor
- HIF1α and cancer
- HIF2α and clear cell renal cell carcinoma
- Clear cell renal cell carcinoma therapeutics based on HIF2α biology
- HIF2α inhibitors and cancer
- Clinics care points
- Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
- Key points
- Introduction
- Immunobiology of renal cell carcinoma
- Metabolic dysregulation in renal cell carcinoma
- Summary
- Clinics care points
- Disclosure
- Hereditary Renal Cell Carcinoma Syndromes
- Key points
- Introduction
- Criteria for genetic evaluation of patients with renal cell carcinoma
- Established renal cell carcinoma hereditary syndromes and clinical presentation
- Screening guidelines
- Summary
- Funding
- Clinics care points
- The Role of the Pathologist in Renal Cell Carcinoma Management
- Key points
- Introduction
- Classification of renal cell tumors: recent updates
- Staging, grading, and other prognostic factors reported by pathologists
- The role of pathologists in the development of personalized medicine strategies for renal cell carcinoma
- Summary
- Clinics care points
- Insights into Renal Cell Carcinoma with Novel Imaging Approaches
- Key points
- Introduction
- Summary
- Clinics care points
- Conflicts of interest
- Surgical Management of Localized Disease and Small Renal Masses
- Key points
- Introduction
- Preoperative evaluation and risk stratification
- Nonsurgical management options
- Surgical management
- Summary
- Clinics care points
- Financial Disclosures/Conflicts of interest
- Role of Surgery in Metastatic Renal Cell Carcinoma
- Key points
- Cytoreductive nephrectomy and cytokine therapies
- Surgery and the evolving landscape of systemic therapies
- Contemporary role of surgery for metastatic renal cell carcinoma
- Summary
- Clinics care points
- Funding
- Disclosure
- Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
- Key points
- Introduction and rationale
- Adjuvant Therapy
- Adjuvant trials with immune checkpoint inhibitor
- Adjuvant treatment with PD-1 inhibition
- Discussion and recommendations
- Clinics care points
- Financial support and sponsorship
- Disclosure
- Role of Radiation in Treatment of Renal Cell Carcinoma
- Key points
- Background and historical context of radiotherapy for renal cell carcinoma
- Radiotherapy for early stage renal cell carcinoma
- Radiotherapy for metastatic renal cell carcinoma
- Clinics care points
- Prognostic Models in Metastatic Renal Cell Carcinoma
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Disclosure
- Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
- Key points
- Introduction
- Programmed cell death ligand 1 (PD-L1) expression
- Genomic biomarkers
- Transcriptomic profiling
- Single-cell profiling
- Gut microbiome
- Summary
- Clinics care points
- Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Disclosure
- First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Key points
- Introduction and background
- Historical trials
- Front line systemic therapy
- Discussion
- Future directions
- Summary
- Clinics care points
- Disclosure
- Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
- Key points
- Introduction
- Rationale for treatment
- Tyrosine kinase inhibitors
- Immunotherapy
- Novel therapies and combinations
- Summary
- Funding
- Disclosures
- Renal Cell Carcinoma of Variant Histology: Biology and Therapies
- Key points
- Introduction
- Systemic therapies for variant histology renal cell carcinoma
- Management of papillary renal cell carcinoma
- Management of chromophobe renal cell carcinoma
- Management of microphthalmia transcription factor renal cell carcinomas
- Management of fumarate hydratase-deficient renal cell carcinoma
- Management of renal medullary carcinoma
- Management of collecting duct carcinoma
- Management of unclassified renal cell carcinoma
- Sarcomatoid or/and rhabdoid dedifferentiation
- Adjuvant therapy considerations
- Summary
- Clinics care points
- Disclosures
- Toxicity Management of Systemic Kidney Cancer Therapies
- Key points
- Background on metastatic renal cell carcinoma and relevance of topic
- Small molecule inhibitors of vascular endothelial growth factor receptors and mammalian target of rapamycin
- Immune checkpoint inhibitors
- Immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor combination therapies
- Hypoxia-inducible factor-2alpha inhibitors
- Concluding remarks
- Clinics care points
- Disclosure
- Management of Brain Metastases in Metastatic Renal Cell Carcinoma
- Key points
- Introduction
- Current studies
- Summary
- Clinics care points
- Disclosure
- Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
- Key points
- Introduction
- Hypoxia-inducible factor 2α inhibition
- Cyclin-dependent kinase 4/6 inhibition
- Targeting metabolic dysregulation
- Novel receptor tyrosine kinase (RTK) inhibitors
- Histone deacetylase pathway inhibition
- Antibody-drug conjugates
- Summary
- Disclosure statement
- Supplementary data
- Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
- Key points
- Introduction
- Immune checkpoints
- Myeloid receptors
- Cytokine therapy
- Role of the microbiome
- Immuno-metabolic pathways
- Adoptive T-cell therapy
- Vaccines
- Summary
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 37-5
- Published: September 15, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780323938990
- eBook ISBN: 9780323939003
BM
Bradley A. Mcgregor
TC